Search results
Results From The WOW.Com Content Network
The following are list of bioCSL flu vaccine brands: [31] Trivalent. Afluria, also marketed as Enzira, Fluvax, and Nilgrip in various different markets. Agrippal, also marketed as Begripal, Fluazur, Sandovac, Agriflu, and Chiroflu in various different markets. Fluad, [32] [1] also marketed as Chiromas in Spain.
Hoechst AG ( German pronunciation: [ˈhøːçst]) was a German chemicals, later life sciences, company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.
The company also completed a secondary public offering in October 2000, generating further net proceeds of $119.5 million. [22] AMRI’s Allegra patent applications, from 1995, and the resulting patents were licensed to what is now Sanofi-Aventis. The company continues to receive royalties on the sale of Allegra and Telfast products globally. [23]
Drugmaker Sanofi's consumer healthcare division has attracted interest from private equity funds as the French group prepares to spin out the business, two sources close to the matter told Reuters.
It was also known as the Alnwick Research Center. It was part of the Sterling Research Group, owned by Sterling Drug. It was taken over by Sanofi-Aventis, run by Sanofi R&D . Former research took place at the Winthrop Laboratories site near the current Fawdon Metro station, which became Sanofi, on Edgefield Avenue in Fawdon; this site made ...
Biotech company Dendreon (NAS: DNDN) and French pharma giant Sanofi (NYS: SNY) announced layoffs earlier this week. What do these staff reductions signify for the companies and investors? Let's ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its insulin production site in Frankfurt, Germany. The site ...